Alphavirus infection triggers antiviral RNAi immunity in mammals

Cell Rep. 2023 May 30;42(5):112441. doi: 10.1016/j.celrep.2023.112441. Epub 2023 Apr 26.

Abstract

RNA interference (RNAi) is a well-established antiviral immunity. However, for mammalian somatic cells, antiviral RNAi becomes evident only when viral suppressors of RNAi (VSRs) are disabled by mutations or VSR-targeting drugs, thereby limiting its scope as a mammalian immunity. We find that a wild-type alphavirus, Semliki Forest virus (SFV), triggers the Dicer-dependent production of virus-derived small interfering RNAs (vsiRNAs) in both mammalian somatic cells and adult mice. These SFV-vsiRNAs are located at a particular region within the 5' terminus of the SFV genome, Argonaute loaded, and active in conferring effective anti-SFV activity. Sindbis virus, another alphavirus, also induces vsiRNA production in mammalian somatic cells. Moreover, treatment with enoxacin, an RNAi enhancer, inhibits SFV replication dependent on RNAi response in vitro and in vivo and protects mice from SFV-induced neuropathogenesis and lethality. These findings show that alphaviruses trigger the production of active vsiRNA in mammalian somatic cells, highlighting the functional importance and therapeutic potential of antiviral RNAi in mammals.

Keywords: CP: Immunology; CP: Microbiology; Semliki Forest virus; alphavirus; antiviral RNAi; innate immunity; viral siRNA.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alphavirus Infections*
  • Animals
  • Antiviral Agents*
  • Cell Line
  • Mammals / genetics
  • Mice
  • RNA Interference
  • RNA, Small Interfering / genetics
  • Semliki forest virus / genetics
  • Sindbis Virus / genetics
  • Virus Replication

Substances

  • Antiviral Agents
  • RNA, Small Interfering